![]() |
Open for inclusion |
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid TumorsCancer type: HCC, Lung cancer, Melanoma Phase: I/II Principal Investigator: Nyakas Martha Country: NO Keywords: Norway, Oslo, Lung, Melanoma, HCC Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01968109?term=2014-002605-38&rank=1 |